Full-Time

Senior Scientist

Medtech Surgery

Posted on 9/10/2025

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Cincinnati, OH, USA

In Person

This role will be fully on site with 5 days per week in-office.

Category
Medical, Clinical & Veterinary (5)
, , , ,
Requirements
  • Minimum of a Master’s degree is required; Doctorate degree strongly preferred. Fields of study include biological sciences, biomedical engineering, or veterinary medicine.
  • At least 4+ years of Industrial research, academic research, or product development experience required. (2+ years for Doctorate)
  • Knowledge of the requirements of in vivo preclinical study conduct and GLP regulations is required.
  • Demonstrated ability to engage and develop relationships with project leaders to facilitate study execution is required.
  • General knowledge of Preclinical Research is required. Knowledge of US FDA, USDA and other international regulations related to preclinical research is highly desired.
  • Demonstrated ability to work cross functionally is required.
  • Strong communication skills – written/oral/listening.
  • Ability to clearly document and communicate plans and results.
  • Working with minimal supervision.
  • Ability to work as a team member, as well as early team leadership skills.
  • Independent decision-making skills as appropriate.
  • Able to handle multiple tasks and responsibilities.
Responsibilities
  • Collaborate in planning and executing in animate studies supporting Design Validation.
  • May serve as core team member representing the Preclinical Research on project teams.
  • May provide preclinical scientific input on the evaluation of physical safety and efficacy for technologies and products at all stages of the product life cycle.
  • May contribute to the Target Product Profile (TPP), evidence generation strategies, and per NPD stage gate process.
  • May be responsible for creating the Preclinical strategy and plan, and overseeing study execution per project timelines.
  • May attend core team meetings and serves as a single point of contact for communication between the project team and functional groups within the Preclinical Research group.
  • Works cross functionally with Medical Affairs, Safety, Regulatory, and Quality to assess project risks, product safety and efficacy on NPD projects.
  • Communicate and monitor the risks associated to the preclinical evaluation of product concept for projects to ensure success.
  • May collaborate with industrial design and human factors group for usability evaluations. Participate in labs, as needed, to develop understanding of customer unmet needs, potential misuse situations and help interpret customer feedback to R&D team.
  • Communicating progress and milestone status to preclinical leadership, R&D partners, and others.
  • Surveys the literature to identify and conduct competitive product performance assessment and safety risks.
  • Responsible for the design of preclinical functionality and safety animal studies.
  • May sponsor studies at external labs (academic, CRO), as needed, to execute preclinical animal studies.
  • Partner with members of the operations team to ensure external facilities meet JnJ standards for animal use and to generate contracts for vendors.
  • Functions as a Good Laboratory Practices Study Director when designated.
  • Is accountable and responsible for Protocol and IACUC Proposal development and approval.
  • Is accountable for procedural data collection, verification, and evaluation.
  • Is accountable for the quality and compliance of the assigned studies.
  • Is accountable and responsible for the Summary Report development and approval.
  • Will function as a Study Coordinator in support of a Study Director.
  • Is responsible collaborating on Protocol and IACUC Proposal development and approval.
  • Is accountable for managing the logistics for lab execution. Such as, lab requests, animal requests, test article management, blood collection, document preparation, and study documentation preparation for archival.
  • Is responsible for investigating and documenting study deviations and non-conformances for Study Director assessment.
  • Is responsible for in life data collection and study execution oversight during surgical procedures.
  • Is responsible collaborating with the Study Director on the Summary Report development and approval.
  • Facilitate support for the conduct, monitoring and reporting, of preclinical studies (Service, Evaluations, and Protocol, and GLP Protocol) in Preclinical Research facilities via the coordination of communications, documentation, and test/control article logistics.
  • Serves as the single point of contact with the Study Director to communicate timelines, issues, and milestones regarding study conduct.
  • Responsible for communicating business related issues or opportunities to next management level.
  • Responsible for ensuring personal and Company compliance with all Federal, State, local and Company regulations, policies, and procedures.
  • Performs other duties assigned as needed.
Desired Qualifications
  • Experience with large animal preclinical studies is highly desired.
  • Knowledge of US FDA, USDA and other international regulations related to preclinical research is highly desired.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE